studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 1119A
including each score, to find independent variables related to
adverse events: a) CCI [HR 2.66(95%CI 1.53-4.65);p=0.001];
b) mCCI [HR 2.35(95%CI 1.61-3.42);p=0.0001] and albumin
[HR 0.99(95%CI 0.99-1.00);p=0.040]; c) CirCom [HR
4.48(95%CI 1.98-10.14);p=0.0001] and albumin [HR
0.997(95%CI 0.995-0.999);p=0.040]. Conclusion: HCV
patients with higher basal comorbidities are at risk of suffering
adverse events during first months of treatment. Charlson and
CirCom comorbidities index appear to be important to evaluate
the overall benefit of the HCV treatment, beyond of the
eradication of the virus. Partients with a Charlson >3 requires
individual analysis before starting DAA therapy.
Disclosures:
Jose Miguel Rosales-Zabal - Speaking and Teaching: janssen
Manuel Romero-Gomez - Advisory Committees or Review Panels: Roche Farma,SA.,
MSD, S.A., Janssen, S.A., Abbott, S.A.; Grant/Research Support: Ferrer,
S.A.
The following authors have nothing to disclose: Javier Ampuero, Carlota Jimeno,
Angela Rojas, A. Ortega, Marta Maraver, Raquel Millán, Blanca Fombuena,
Ramón Morillo, J. M. Navarro, Raul J. Andrade
1864
Perceived risk and HCV knowledge in a high risk nonbaby
boomer population from a community based testing
model
Stephanie Tzarnas, Allison Brodsky, Hunana Chaudhry, Carla
Coleman, Michelle Dougherty, Lora Magaldi, Carolyn Moy,
Ta-Wanda Preston, Stacey B. Trooskin; Drexel University College
of Medicine, Philadelphia, PA
Background: Hepatitis C is the most common blood-borne
infection in the US with a prevalence of 1.6%. CDC guidelines
recommend high-risk individuals and individuals born between
1945-1965 be tested for HCV. High-risk individuals may not
be tested due to lack of access to primary care or because providers
may not routinely assess risk factors. We aim to assess
perceived risk for contracting HCV as well as HCV knowledge
in a community based HCV testing program serving high risk
individuals. Methods: Community based testing was conducted
by two community based organizations. A brief survey was
utilized to assess general demographic information, perceived
risk of HCV infection, and HCV knowledge. Results: 1,587
patients were tested from June-April 2015, 11.3% were antibody
positive. Of the 1,587 individuals tested, 67% were born
outside of the birth cohort. Of the 1,063 individuals tested
outside of the birth cohort, 9.3% were HCV antibody positive.
80% of individuals born outside of the birth cohort with reactive
antibody test received confirmatory NAT testing. Of those
individuals; 81% were chronically infected; only 3.2% had
seen their PCP in the last 12 months. Notably, 97% of HCV
antibody positive individuals outside of the birth cohort had
histories of drug use; of this group 47% had injected drugs
and 66% of those individuals admitted to sharing injection
equipment. Of the HCV antibody positive individuals outside
of the birth cohort, 75% had heard of HCV; 66% answered
that there was a cure for HCV, and 33% believed that there
was a vaccine for HCV. Of the non-baby boomer antibody
positive individuals, 40% rated themselves high risk for contracting
HCV, 15% rated themselves low risk, 11% rated themselves
moderate risk, and 9% rated themselves not at risk for
contracting HCV. Conclusions: Community based testing and
linkage to care programs serving high risk individuals have
the potential to engage individuals in subspecialty care, where
the standard health care system may have failed to do so.
Interestingly, many of the non-baby boomer antibody positive
individuals rated their perceived risk for contracting HCV high,
while few rated themselves not at risk. Community based testing
programs are needed to ensure that high risk individuals
outside of the 1945-1965 birth cohort receive proper HCV
testing, treatment, and education.
Disclosures:
Stephanie Tzarnas - Grant/Research Support: Gilead Sciences
Allison Brodsky - Grant/Research Support: Gilead
Hunana Chaudhry - Grant/Research Support: Gilead Sciences
Carla Coleman - Grant/Research Support: Gilead Sciences
Michelle Dougherty - Employment: Opening Doors for Diverse Populations to
Health Dispairites Research Under the NIH 1R25MD006792-01 The National
Institute on Minority Health and Health Disparities (NIMHA) Dr. Shannon Marquez,
PI; Grant/Research Support: Gilead Sciences
Lora Magaldi - Grant/Research Support: Gilead Sciences
Carolyn Moy - Grant/Research Support: Gilead
Stacey B. Trooskin - Advisory Committees or Review Panels: Gilead Sciences;
Grant/Research Support: Gilead Sciences
The following authors have nothing to disclose: Ta-Wanda Preston
1865
Investigation into the high prevalence of hepatitis C
virus infection in a rural village in southwest China
Shiqi Tao 1 , Guangyu Huang 1 , Li Wang 1,2 , Dengming He 1 , Zehui
Yan 1 , Shitao Ding 1 , Yunjie Dan 1 , Cheng Xu 1 , Xianghua Zeng 1 ,
Xiaohong Wang 1 , Yuming Wang 1 ; 1 Department of infectious
diseases, Southwest Hospital, Third Military Medical University,
Chongqing, China; 2 Medical college of Guiyang, Guiyang, China
Purpose: To clarify the changing pattern of hepatitis C virus
(HCV) prevalence in China, with the aim of developing appropriate
and effective strategies for the prevention and treatment
of this significant emerging disease. Methods: The residents of
Village M, located in southwest China, voluntarily participated
in this study. Blood samples were obtained and anti-HCV titers
were tested to determine the HCV status of the participants.
For those who were anti-HCV positive, HCV RNA levels and
genotypes were subsequently tested. HBV-related factors and
anti-HIV titers were also tested. In addition, the methodology
historically used to sterilize needles in the medical center used
by the villagers was recreated to test the effectiveness of this
procedure. Results: Anti-HCV antibody testing showed that 258
(50.4%) of the 512 participants were anti-HCV positive. The
majority (180/258) of anti-HCV positive participants were also
HCV RNA positive. Genotyping based on NS5B sequences
showed that the predominant subtype of HCV was 3b (96.0%),
followed by 6a (2.0%) and 1b (2.0%). The recreated medical
procedure indicated that the transmission route might have
been inadequately sterilized needles. The HBV infection rate
among participants was 34.4% and the HBV/HCV co-infection
rate was 17.6%, but none of the participants were anti-HIV
positive. Conclusions: HCV infection was found to be highly
prevalent in a village in southwest China. A new transmission
or prevalence pattern of HCV infection was identified that
involved inadequately sterilized needles. Co-infection with HBV
among the anti-HCV positive individuals was also common.